Treatment of anemia in patients with chronic heart failure

Journal of Cardiac Failure

Volumn 10, Issue 1 SUPPL., 2004, Pages

  Katz, Stuart D ^a   Mancini, Donna ^b   Androne, Ana Silvia ^a   Hryniewicz, Katarzyna ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

blood volume; Erythropoietin; exercise; heart failure; vascular resistance

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; HEART FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY DISEASE; MORBIDITY; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; KIDNEY FAILURE; RANDOMIZED CONTROLLED TRIAL;

ANEMIA; CHRONIC DISEASE; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE; MORBIDITY; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 2942522435     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2004.01.002     Document Type: Article

References (29)

1. Winearls C.G. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant. 13:(Suppl 2):1998;3-8
2. Erslev A.J. Erythropoietin. N Engl J Med. 324:1991;1339-1344
3. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 316:1987;73-78
4. Eschbach J.W., Abdulhadi M.H., Browne J.K., Delano B.G., Downing M.R., Egrie J.C., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 111:1989;992-1000
5. McMahon F.G., Vargas R., Ryan M., Jain A.K., Abels R.I., Perry B., et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood. 76:1990;1718-1722
6. Macdougall I.C. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant. 13:(Suppl 2):1998;23-27
7. Leyland-Jones B. Evidence for erythropoietin as a molecular targeting agent. Semin Oncol. 29:2002;145-154
8. Magnanti M., Gandini O., Giuliani L., Gazzaniga P., Marti H.H., Gradilone A., et al. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood. 98:2001;2872-2874
9. Sterin-Borda L., Barcelo A.C., Bozzini C.E. Erythropoietin improves cardiac contractility in post-hypoxic mice. Br J Haematol. 121:2003;180-186
10. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 8:2002;495-505
11. Becerra S.P., Amaral J. Erythropoietin - an endogenous retinal survival factor. N Engl J Med. 347:2002;1968-1970
12. Goldberg N., Lundin A.P., Delano B., Friedman E.A., Stein R.A. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J. 124:1992;424-427
13. London G.M., Zins B., Pannier B., Naret C., Berthelot J.M., Jacquot C., et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int. 36:1989;878-882
14. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int. 61:(Suppl 80):2002;35-38
15. Portoles J., Torralbo A., Martin P., Rodrigo J., Herrero J.A., Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 29:1997;541-548
16. Hayashi T., Suzuki A., Shoji T., Togawa M., Okada N., Tsubakihara Y., et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 35:2000;250-256
17. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 339:1998;584-590
18. Foley R.N., Parfrey P.S., Morgan J., Barre P.E., Campbell P., Cartier P., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 58:2000;1325-1335
19. Furuland H., Linde T., Ahlmen J., Christensson A., Strombom U., Danielson B.G. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 18:2003;353-361
20. Silverberg D.S., Wexler D., Blum M., Tchebiner J.Z., Sheps D., Keren G., et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 18:2003;141-146
21. Silverberg D.S., Wexler D., Blum M., Keren G., Sheps D., Leibovitch E., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 35:2000;1737-1744
22. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 37:2001;1775-1780
23. Mancini D.M., Katz S.D., Lang C.C., LaManca J., Hudaihed A., Androne A.S. The effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 107:2003;294-299
24. Macdougall I.C., Cooper A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 17:(Suppl 11):2002;39-43
25. Trivedi H.S., Brooks B.J. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron. Am J Nephrol. 23:2003;78-85
26. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica. 87:2002;1209-1221
27. Macdougall I.C. Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int Suppl. 2002;55-61
28. Macdougall I.C., Matcham J., Gray S.J. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant. 18:2003;576-581
29. Locatelli F., Canaud B., Giacardy F., Martin-Malo A., Baker N., Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant. 18:2003;362-369